Assetmark Inc. boosted its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 6.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,287 shares of the company’s stock after acquiring an additional 201 shares during the quarter. Assetmark Inc.’s holdings in argenx were worth $1,225,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. KB Financial Partners LLC lifted its holdings in shares of argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 45 shares during the period. CI Investments Inc. raised its holdings in argenx by 202.6% during the fourth quarter. CI Investments Inc. now owns 79 shares of the company’s stock worth $30,000 after purchasing an additional 156 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in argenx during the fourth quarter worth $37,000. Captrust Financial Advisors raised its holdings in argenx by 116.7% during the first quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock worth $45,000 after purchasing an additional 77 shares during the last quarter. Finally, Fortis Capital Advisors LLC acquired a new position in argenx during the fourth quarter worth $70,000. 55.90% of the stock is owned by institutional investors and hedge funds.
argenx Trading Up 1.0 %
ARGX stock opened at $502.92 on Friday. The stock has a 50-day moving average price of $432.61 and a two-hundred day moving average price of $397.46. argenx SE has a 12-month low of $333.07 and a 12-month high of $550.76. The company has a market cap of $29.44 billion, a PE ratio of -70.14 and a beta of 0.74.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Bank of America lifted their price objective on argenx from $446.00 to $572.00 in a report on Tuesday, July 18th. JMP Securities reduced their price objective on argenx from $448.00 to $445.00 in a report on Friday, May 5th. Wedbush reaffirmed an “outperform” rating and set a $570.00 price objective on shares of argenx in a report on Tuesday, July 18th. UBS Group downgraded argenx from a “buy” rating to a “neutral” rating and raised their price target for the stock from $480.00 to $570.00 in a research report on Monday, July 24th. Finally, Morgan Stanley raised their price target on argenx from $452.00 to $602.00 and gave the stock an “overweight” rating in a research report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $521.59.
View Our Latest Stock Report on argenx
About argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.
Featured Articles
- Five stocks we like better than argenx
- The “How” and “Why” of Investing in 5G Stocks
- Alibaba Explodes On Earnings, Inching Toward Triple Digit Prices
- Upcoming IPO Stock Lockup Period, Explained
- Is It Time To Game The Roblox Market?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 2 Cheap Stocks The Insiders Are Buying
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.
